Screening

 
Teledermatology-Dermoscopy Program Could Help Reduce Inequities in Skin Cancer Screening
June 20, 2025

A student-led teledermatology-dermoscopy initiative that identified skin lesions in underserved communities could be a scalable model for early skin cancer detection and care.

PATHFINDER 2 Study Shows Improved Performance of Galleri Multicancer Detection Test
June 19, 2025

GRAIL announced that both cancer detection and positive predictive value with Galleri were substantially higher than in the earlier published PATHFINDER study.

Early Colorectal Cancer Screening at Ages 40-49 Reduces Long-Term Incidence and Mortality
June 18, 2025

As the incidence of young-onset colorectal cancer continues to rise, the findings from a large Taiwanese population-based study support lowering the age for initial screening.

GLP-1s May Cut Obesity-Related Cancer Risk: Daily Dose
June 13, 2025

Your daily dose of the clinical news you may have missed.

Joint FDA Studies Show DermaSensor Device Reduces Missed Skin Cancers in Primary Care by 50%
June 12, 2025

FDA-cleared DermaSensor device shows 96% sensitivity and reduces missed skin cancer diagnoses by 50% in primary care, according to new data.

New Study Highlights Lengthy Journey to Phase Out Low-Value Cancer Screenings in the US
June 12, 2025

Valid and accessible measures are needed to monitor low-value care practices and set benchmarks for de-implementation efforts, researchers reported.

Older Adults are Open to Cognitive Assessment for Dementia in Primary Care But Obstacles Loom Large, a New Study Finds
June 05, 2025

A study reveals low clinician engagement in digital cognitive assessments for dementia in primary care, highlighting workflow and other barriers to early detection.

Guardant Health's Shield Mutlicancer Detection Blood Test Granted FDA Breakthrough Device Designation
June 04, 2025

Breakthrough device designation for the multicancer detection test is supported by clinical validation data demonstrating an overall specificity of 98.6% and sensitivity of 60%.

ctDNA Blood Test Showed High Sensitivity, Specificity for Colorectal Cancer but Poor Sensitivity for Advanced Precancerous Neoplasia
June 03, 2025

A new study of a circulating tumor DNA-based screening test revealed promising sensitivity and specificity for for CRC, but only 12.5% sensitivity for advanced neoplasia.

OASIS-4 Trial: Elinzanetant Reduces Frequency of Vasomotor Symptoms Related to Endocrine Therapy for HR-Positive Breast Cancer
June 03, 2025

ASCO 2025. Elinzanetant significantly reduced the frequency of VMS vs placebo in women on endocrine therapy for treatment or prevention of HR+ breast cancer.